



IN THE GRAND COURT OF THE CAYMAN ISLANDS
FINANCIAL SERVICES DIVISION

CAUSE NO. FSD 391 OF 2023 (JAJ)

IN THE MATTER OF SECTION 86 OF THE COMPANIES ACT (2023 REVISION)

AND IN THE MATTER OF YESTAR HEALTHCARE HOLDINGS COMPANY LIMITED (巨星醫療控股有限公司)

PETITION

To: The Grand Court of the Cayman Islands

This humble petition (the *Petition*) of Yestar Healthcare Holdings Company Limited (巨星醫療控股有限公司) (the *Company*), whose registered office is located at Cricket Square, Hutchins Drive, P.O. Box 2681, George Town, Grand Cayman, KY1-1111, Cayman Islands shows that:

INTRODUCTION

- 1 The Company was incorporated in the Cayman Islands under the Companies Act (the *Companies Act*) on 1 February 2012 as an exempted company with limited liability and registration number 265992.
- 2 The Company intends to promulgate a scheme of arrangement (the *Scheme*) between it and a single class of certain of its creditors (the *Scheme Creditors*) pursuant to section 86

of the Companies Act. The object of the Petition is to seek the sanction of this Honourable Court of the Scheme. A copy of the Scheme will be exhibited to a supplemental affirmation made by a director of the Company, which will be filed with this Honourable Court.

- 3 The Scheme is part of the Company's efforts to implement a restructuring of the liabilities of the Company (the **Restructuring**) under notes issued by the Company in an aggregate principal amount of US\$197,864,523 due 2026 (the **Notes**) pursuant to an indenture dated 30 December 2021 (as amended, supplemented, or otherwise modified from time to time, the **Indenture**) between, amongst others, the Company, the Subsidiary Guarantors (defined below) and Madison Pacific Trust Limited as successor trustee (**Notes Trustee**) and security agent (**Security Agent**) of the Bank of New York Mellon, London Branch and The Bank of New York Mellon, Hong Kong Branch, respectively.

THE COMPANY

- 4 The Company is the ultimate holding company of certain directly or indirectly owned subsidiaries (together with the Company, the **Yestar Group**), located across various jurisdictions including the Cayman Islands, British Virgin Islands (**BVI**), Hong Kong and the People's Republic of China (**PRC**).
- 5 Following its incorporation, the Company changed its name from Yestar International Company Limited by way of special resolution dated 8 March 2012 and subsequently changed its name to its current name by way of special resolution dated 11 January 2017.
- 6 The Company is registered as a non-Hong Kong company in Hong Kong with registration number F0019103. The shares of the Company have been listed on the main board of the Stock Exchange of Hong Kong (**HKEx**) since 11 October 2013, with Stock Code 2393.

BUSINESS OF THE GROUP

- 7 The principal activities of the Yestar Group comprise the distribution of In Vitro Diagnostic (**IVD**) products in the PRC, and the manufacture of medical films used in X-Ray, Magnetic Resonance Imaging (MRI) and Computer Tomography (CT-scan) for Fujifilm in the PRC. The Yestar Group also

manufactures, markets, and sells dental film and medical dry film products under the house brand “Yes!Star”. The Yestar Group is one of the largest distributors and service providers of IVD products in the PRC. As of 30 June 2023, the Yestar Group had an IVD distribution network covering nine provinces and four tier-1 cities in the PRC, with coverage of 1,588 hospitals and clinics.

- 8 The principal assets of the Company comprise shares in its wholly owned subsidiary, Yestar Asia Company Limited (**Yestar BVI**), a company incorporated with limited liability under the laws of the BVI on 1 February 2012 which, in turn, holds 100% of the share capital of Yestar International (HK) Company Limited (**Yestar HK**), a company incorporated with limited liability under the laws of Hong Kong on 29 February 2012. Yestar HK is the holding company of three PRC companies which in turn hold or control other PRC operating companies of the Yestar Group.

THE FINANCIAL POSITION OF THE COMPANY AND THE YESTAR GROUP

Assets

- 9 As at 30 June 2023, the Company’s non-current assets amounted to approximately RMB877,147,612 (US\$121,391,090¹) and the Company’s current assets amounted to approximately RMB2,597,627,091 (US\$359,493,406), which primarily consisted of the following:
- (a) **Property, plant, and equipment** – the Company owns certain equipment valued at RMB212,770,128 (US\$29,445,896);
 - (b) **Cash and cash equivalents** – RMB281,982,549 (US\$39,024,411);
 - (c) **Trade and other receivables** – RMB1,632,982,954 (US\$225,993,410);
 - (d) **Intercompany receivables** – amounts owing to the Company from other subsidiaries in the Yestar Group were RMB11,725,377,589 (US\$1,622,709,955); and
 - (e) **Investment in subsidiaries** – the Company’s equity interest in its direct subsidiaries is valued at RMB37,801,505 (US\$5,231,464).

¹ Conversion rate to US\$ is RMB 1 = US\$ 0.138393, which is equivalent to US\$1 = RMB7.23.

- 10 As at 30 June 2023, Yestar Group's non-current assets on a consolidated basis amounted to approximately RMB877,147,612 (US\$121,391,090) and the Yestar Group's current assets on a consolidated basis amounted to approximately RMB2,597,627,091 (US\$359,493,406).
- 11 As at 30 June 2023, Yestar Group's key assets primarily relate to the following:
- (a) **Trade and other receivables (revenue)** - revenue of approximately RMB2,363.0 million (US\$327.02 million) as compared with approximately RMB4,294.0 million (US\$594.26 million) as at 31 December 2022, which mainly comprised the distribution of IVD products. Specifically, the distribution of IVD products segment had contributed 94.1% of revenue of the Yestar Group as compared to 93.9% for the year ended 31 December 2022. In addition, segment revenue amounted to approximately RMB2,223.7 million (US\$307.74 million) compared to RMB4,030.4 million (US\$557.78 million) for the year ended 31 December 2022).
 - (b) **Unrestricted cash and cash balance** – unrestricted cash and cash balance of approximately RMB282.0 million (approximately US\$39.2 million).

Liabilities

- 12 As at 30 June 2023, the Company owed approximately RMB1,711.9 million (US\$236.92 million) in principal amount of financial indebtedness to third party financial creditors and noteholders, which consisted of:
- (a) **the Notes** – which as at the date of this Petition, US\$194,506,648 in principal amount of the Notes are outstanding; and
 - (b) **interest-bearing bank and other borrowings** – in the total amount of approximately RMB285.43 million (approximately US\$39.5 million.)

- 13 As at 30 June 2023, the Yestar Group's non-current liabilities on a consolidated basis amounted to approximately RMB186,494,897 (US\$25,809,588) and the Yestar Group's current liabilities on a consolidated basis amounted to approximately RMB 3,685,424,548 (US\$510,036,959).
- 14 The Company is proposing to restructure the liabilities of the Company and the Subsidiary Guarantors in respect of the Notes by way of the Scheme. Under the terms of the Scheme, the Notes will be cancelled and, subject to applicable laws, Scheme Creditors will receive their rateable share of the Redemption Amount, and if applicable, the Consent Fee, and Work Fee (defined below).

BACKGROUND TO THE RESTRUCTURING

- 15 Since early 2020, the Yestar Group has experienced deteriorating market conditions and a series of events negatively impacted its financial condition. During the first half of 2020, hospital resources and demand for medical supplies were focused almost exclusively on combatting Covid-19, which caused a plunge in demand for the Yestar Group's core products and a resultant worsening of the Yestar Group's liquidity problems. The negative impact of the Covid-19 pandemic exacerbated and amplified an already challenging market environment, and adversely affected the Yestar Group's liquidity position.
- 16 In early 2021, in order to improve Yestar Group's liquidity and cash flows, the Yestar Group explored refinancing options onshore but was unsuccessful as a result of the mounting concerns from onshore lenders around the overall outlook of the Company. It became apparent to the Yestar Group and the Company at the beginning of 2021 that, despite the measures undertaken to mitigate the financial impact of the Covid-19 pandemic and the resultant decline in revenue, a more holistic and long-term solution would be required to address the maturity of the then outstanding and unpaid US\$200,000,000 6.9% senior notes due 2021 issued by the Company.
- 17 The Company completed the restructuring of the notes due 2021 by way of a scheme of arrangement in the Cayman Islands. The scheme was approved by the Cayman court on 10 December 2021 and the effective date of that restructuring occurred on 30 December 2021.

- 18 In connection with the restructuring in 2021, the Company issued the Notes guaranteed by Yestar BVI and Yestar HK (together, **Subsidiary Guarantors**). However, market conditions remained extremely challenging and Yestar Group's liquidity position deteriorated further to a level that did not enable the members of the Yestar Group to maintain sufficient funds to discharge their liabilities as they arose.
- 19 The Company had been exploring various ways to improve the financial position of the Yestar Group, secure the future of its business and extend its liquidity runway. The Board of the Company successfully negotiated a sale of 94.2% of the Company's equity interests in Shanghai Emphasis Investment, Shanghai Jianchu Medical, Shanghai Chaolian Trading, Shanghai Haole Industrial and Shanghai Dingpei Industrial for an aggregate consideration of RMB574,750,000 (approximately US\$53.0 million) (**Asset Disposal**). On 30 December 2022, the Company entered into an equity transfer agreement and made an announcement with respect thereto on the same date on the HKEx in respect of the Asset Disposal (**Equity Transfer Agreement**). It is contemplated that the net proceeds from the Asset Disposal (the **Equity Transfer Consideration**) will be fully applied towards the Redemption Amount (defined below). The Redemption Amount will in turn partially discharge the Company's and Subsidiary Guarantors liabilities under the Notes.
- 20 The Company was unable to resolve its liquidity shortfall in time and failed to meet its obligations to make a partial redemption payment and pay the relevant interest payment due under the Notes. Pursuant to the Indenture, the Notes continue to be in default.
- 21 While there has been liquidity and other issues, some objective improvements in 2023 included:
- (a) The Yestar Group recorded increased revenue and profit in the six months ended 30 June 2023 compared to the same period in 2022.
 - (b) The Company recorded a total revenue of RMB2,363.0 million (approximately US\$327.02 million) for the six months ended 30 June 2023, a 20.2% increase from the revenue of RMB1,966.1 million (approximately US\$272.09 million) recorded for the same period in 2022;

- (c) Net profit for the six months ended 30 June 2023 amounted to RMB11.6 million (approximately US\$1.61 million), compared to net loss of RMB184.0 million (approximately US\$25.46 million) for the same period in 2022;
 - (d) At the business segments level, revenue of medical businesses and non-medical businesses for the six months ended 30 June 2023 amounted to RMB2,223.7 million (approximately US\$307.74 million) and RMB139.3 million (approximately US\$19.28 million) respectively, representing a 20.8% and 11.6% increase as compared to the same period in 2022 respectively for the two segments; and
 - (e) Gross profit margins of medical businesses and non-medical businesses increased from 16.2% and negative 3.3% for the six months ended 30 June 2022 to 21.4% and 20.4% for the same period in 2023, respectively.
- 22 Notwithstanding a successful restructuring in 2021 and some objective improvements in 2023, market conditions and Yestar Group's current operating environment have remained extremely challenging, and the Yestar Group has not yet reached its pre-Covid-19 operating levels, revenue, and margin, in particular: for the year ended 2018, Yestar Group's total revenue was RMB4,447.0 million (approximately US\$615.43 million) and gross profit margin was 27.0%. In comparison, as at 30 June 2023, Yestar Group's revenue was approximately RMB2,363.0 million (US\$327.02 million) and gross profit margin was 21.1%, representing a 5.9% decrease.
- 23 Nevertheless, despite these limited improvements, as at 30 June 2023 the Yestar Group had an unrestricted cash and bank balance of approximately RMB282.0 million (approximately US\$39.02 million). The Yestar Group's liquidity position has continued to deteriorate to a level that does not enable it to maintain sufficient funds to discharge its liabilities as they arise. In particular, the Company expects to be unable to repay its liabilities under the Notes if Noteholders exercise their acceleration rights to bring forward the repayment date of the Notes in the event that the Scheme fails. As such, the Company is currently insolvent on a cash flow basis.
- 24 The Company appointed Dechert as global legal advisors and Admiralty Harbour Capital Limited as financial advisor, in or around April 2023, respectively, with a view to facilitating the

implementation of the restructuring of the Company and Subsidiary Guarantors indebtedness and liabilities under the Notes. In addition, the Company appointed Harney Westwood & Riegels as its Cayman Islands counsel in relation to the Restructuring and the Scheme.

- 25 Together with its financial advisor and legal advisors, the Company carried out extensive negotiations and discussions with certain significant beneficial holders of the Notes, including an ad hoc group (comprising certain Scheme Creditors who represent approximately 47.8% of the outstanding principal amount of the Notes as at the date of this Petition) (**Committee**).
- 26 These discussions were guided by the Yestar Group's ongoing objective of implementing a financial restructuring that will reduce the short-term debt burden and address the current liquidity issues of the Yestar Group, leaving it with a sustainable capital structure that is more likely to enable the Company and its subsidiaries to comply with their post-restructuring obligations and liabilities and to trade on a going concern basis to deliver long term value for all of its stakeholders.
- 27 Further to such discussions, on 30 November 2023, the Company and the Subsidiary Guarantors (among others) entered into a restructuring support agreement (the **Restructuring Support Agreement**) with the Committee (which was updated in accordance with its terms on 5 December 2023). The Restructuring Support Agreement appended the term sheet setting out the key terms of the Restructuring of the Notes.
- 28 At time of the launch of the Restructuring Support Agreement on 6 December 2023, holders of the Notes holding an aggregate principal amount of approximately US\$93 million of Notes then outstanding (representing approximately 47.8% of the aggregate outstanding principal amount of all Notes) had acceded to or submitted accession documents to accede to the Restructuring Support Agreement.
- 29 As of the date of this Petition, more than 26 holders of the Notes representing approximately 61.99% of the aggregate outstanding principal amount of the Notes have acceded to the Restructuring Support Agreement. Scheme Creditors who have acceded to the Restructuring Support Agreement are required, under its terms and subject to certain conditions being satisfied, to take all commercially reasonable actions within their power which they are reasonably

requested by the Company to take to support the Restructuring and vote in favour of the Scheme. Scheme Creditors of the remaining outstanding Notes are still encouraged to accede to the Restructuring Support Agreement, which will remain open for accession until the **Record Time** (to be defined in the Scheme). However, for the avoidance of doubt, such Scheme Creditors will not be eligible to receive their share of the Consent Fees (as defined in paragraph 47 below) if such Scheme Creditors do not accede to the Restructuring Support Agreement by 5.00 p.m. Hong Kong time on 5 January 2024 (or such later date and time as the Company may elect in its sole discretion) (**Consent Fee Deadline**) and fulfil the other conditions for receipt of the same as set out in the Restructuring Support Agreement, for example, the requirement to hold the relevant Notes at the Record Time.

- 30 The Restructuring seeks to fully compromise and discharge the obligations of the Company and the Subsidiary Guarantors, arising, directly or indirectly, in relation to, or arising out of or in connection with, the Notes. Specifically, under the terms of the Scheme, the Notes will be cancelled and, subject to applicable laws, Scheme Creditors will receive their rateable share of the Redemption Amount, and if applicable, the Consent Fee and Work Fee (defined below).

DEBTS SUBJECT TO THE SCHEME

- 31 The Scheme relates to the compromise of debts owed by the Company and/or guaranteed by the Subsidiary Guarantors under Notes. Based on the terms of the Indenture, the Notes bore interest at 9.5% per annum which is payable semi-annually in arrears on 15 March and 15 September of each year, and the Company was due to redeem 5% of the original principal amount of the Notes by 30 December 2022.
- 32 The Notes are obligations owed by the Company under the Indenture. The Notes are listed and quoted on the Singapore Exchange Securities Trading Limited (ISINs for the global notes are XS2407822274 (RegS), XS2407822357 (144A), and XS2407823249 (IAI)).
- 33 As referred at paragraph 18 above, certain direct and indirect subsidiaries of the Company, being the Subsidiary Guarantors, have granted guarantees in favour of the holders of the Notes in respect of all of the obligations of the Company to pay the principal, premium, if any, and interest under the Notes. Additionally, share charges dated 30 December 2021 were entered into by the

Company as chargor, Yestar BVI as charged company and the Security Agent and the share charge dated 30 December 2021 entered by Yestar BVI as chargor and the Security Agent.

- 34 The Notes and Indenture are governed by New York law.
- 35 The aggregate outstanding principal amount of the Notes is approximately US\$194,506,648 as at the date of this Petition.

Excluded Liabilities

- 36 The claims of the Scheme Creditors (whether principal, guarantee and/or security) against the Company, the Subsidiary Guarantors, and other entities in the Yestar Group, other than claims in respect of the Notes, are not intended to be the subject to the arrangement and compromise effected by the Scheme (the ***Scheme Excluded Liabilities***).
- 37 For the avoidance of doubt, any claim in respect of any liability of the Company that is not subject to the arrangement and compromise to be effected by the Scheme (i.e. liabilities of the Company outside of the Notes), including (without limitation) any claim by a Scheme Creditor against the Company arising out of any failure to fulfil its obligations under the Scheme, any claim by an advisor with respect to any scheme costs, any claim by the Notes Trustee and/or The Bank of New York Mellon, London Branch as common depositary (***Depositary***) for Euroclear Bank S.A./N.V or Clearstream Banking, société anonyme clearing systems (***Clearing Systems***) with respect to any accrued and unpaid fees and expenses due to them or their respective legal and professional advisers under the terms of the Notes / Indenture in respect of the period ending on the Restructuring Effective Date (as defined in the Restructuring Support Agreement and/or the Scheme); and any other claim which the Company reasonably determines should be excluded from the terms of the Scheme are Scheme Excluded Liabilities.
- 38 The Company and Subsidiary Guarantors will enter into a separate deed of release with the Notes Trustee and the Security Agent releasing the Company and Subsidiary Guarantors from any and all liabilities owing to them upon the occurrence of the Restructuring Effective Date.

Scheme Creditors

- 39 A Scheme Creditor for the purposes of the Scheme is any person holding an economic or beneficial interest as principal in any of the Notes. A ***Scheme Claim*** is any claim, save for the Scheme Excluded Liabilities, against the Company and the Subsidiary Guarantors.
- 40 The Company intends to convene a single meeting of Scheme Creditors for the purposes of voting on the Scheme. The Company intends to address why there should only be a single class of Scheme Creditors for the Scheme in a supplemental affirmation and legal submissions to the Court.

OBJECTS AND MECHANICS OF THE SCHEME AND THE RESTRUCTURING

- 41 The primary purpose of the Scheme and the Restructuring is to effect a restructuring of the liabilities of the Company under the Notes.
- 42 Other purposes of the Scheme and the Restructuring are to:
- (a) avoid the Company and other members of the Yestar Group potentially entering into insolvent liquidation (or other appropriate insolvency proceedings) in the near future, as a result of which the anticipated recoveries for the Noteholders may be significantly less than if the Restructuring were to be completed successfully;
 - (b) alleviate cash flow pressure on the Company and other members of the Yestar Group, which will enable them to comply with their obligations and liabilities following the Restructuring, and provide them with increased flexibility in their operations such that they may continue to trade on a going concern basis and to recover as the PRC market stabilises; and
 - (c) increase the prospect of delivering long-term value for the shareholders and other stakeholders of the Company.
- 43 The Restructuring is intended to be implemented through the Scheme, which will affect the rights of the Scheme Creditors. In summary, pursuant to the terms of the Scheme, the Scheme Creditors

will agree to release in full all claims under and in connection with the Notes against the Company save for the Scheme Excluded Liabilities in return for receiving the Redemption Amount in the aggregate amount of US\$60.5 million plus any Step-Up Amount (the **Redemption Amount**). The Step-Up Amount is additional amounts accruing at a rate of six (6) per cent per annum on the Equity Transfer Consideration which should not be less than US\$53 million (or its equivalent in any other currency) from day to day, starting from (and including) the date falling 90 days after the date of completion of the Equity Transfer Agreement to the Restructuring Effective Date.

44 For the purposes of attending the meeting of Scheme Creditors for the purpose of considering and, if thought fit, voting in favour, with or without modification, the Scheme (***Scheme Meeting***), all Scheme Creditors will have their claims admitted as at the Record Time. Any such claims will be admitted without double counting, and without permitting duplicative claims or portions of claims against the Company other than for US\$1, and in any event subject to the discretion of the chairperson of the Scheme Meeting.

45 Pursuant to the Scheme:

(a) the Notes will be discharged and the respective rights and obligations of the Scheme Creditors (including, for the avoidance of doubt, any person that acquires an interest in the Notes after the Record Time), the Company, the Subsidiary Guarantors, and the Notes Trustee towards one another under the Notes and Indenture will terminate and be of no further force and effect;

(b) subject to applicable laws, Scheme Creditors will receive their rateable share of the Redemption Amount on or prior to Restructuring Effective Date in accordance with the terms of the Scheme and the Indenture.

46 The Redemption Amount will be paid to the Scheme Creditors on the Restructuring Effective Date as a redemption payment in accordance with the terms and subject to the conditions of the Notes. The Redemption Amount will be settled through Clearing Systems.

Consent Fee

- 47 Each Scheme Creditor who acceded to the Restructuring Support Agreement (**Consenting Creditor**), by or prior to the Consent Fee Deadline, and who votes in favour of the Scheme will, subject to the terms of the Restructuring Support Agreement, be entitled to receive a share of US\$972,530 (the **Consent Fee**) calculated on the basis of the proportion that the Eligible Restricted Note(s) (as defined in the Restructuring Support Agreement) held in aggregate by that Consenting Creditor bears to the Eligible Restricted Notes held (in aggregate) by all Consenting Creditors at the Record Time. The Consent Fee shall be paid in full and in cash, free and clear of all withholding taxes or other deductions and rounded to the nearest US\$0.01, with half a cent being rounded upwards, and in respect of the Notes; and which will be paid by way of a transfer via the Clearing Systems to the same Clearing System account where the relevant Notes were held on the Record Time or such other method as the Company shall reasonably determine.

Work fee

- 48 Each Consenting Creditor who is a member of the Committee shall also be entitled to receive a share of a one-off fee of US\$1,688,000 (**Work Fee**). Subject to the Scheme being sanctioned by the Court and obtaining of all other approvals or consents in respect of the Restructuring, the Company has agreed on or prior to, and as a condition precedent to, the Restructuring Effective Date, to pay the Work Fee subject to the Scheme.
- 49 A Committee member's rateable share of the Work Fee will be calculated based on the proportion that the Eligible Restricted Notes held (in aggregate) by that member bears to the Eligible Restricted Notes held (in aggregate) by the Committee at the Record Time. The Company considers that the Work Fees are appropriate to compensate certain creditors for the work, time, and (where applicable) risks associated with negotiating the Restructuring, including being restricted from trading at various points during the Restructuring negotiation due to being in receipt of "material non-public information".

Reimbursement of Legal Fees

50 Subject to the Scheme being sanctioned by the Court and obtaining of all other approvals or consents in respect of the Restructuring, the Company has also agreed on or prior to, and as a condition precedent to, the Restructuring Effective Date, to pay an aggregate amount of US\$1,500,000 towards the fees, costs, and expenses of:

- (a) The legal advisors to the Committee; and
- (b) The Notes Trustee and its legal advisors.

ORDERS AND DIRECTIONS

51 The Company intends to make an application for, among other things, orders, and directions:

- (a) That the relevant class of Scheme Creditors affected by the Scheme are those referred to in paragraph 2 above;
- (b) That the Company be at liberty to convene a single meeting of Scheme Creditors (i.e., the Scheme Meeting) for the purpose of considering and, if thought fit, approving, with or without modification, the Scheme; and
- (c) As to the mode of delivery of a scheme document (which includes an explanatory statement and notice of the Scheme Meeting) to the Scheme Creditors and that a record time be set for the purposes of voting at the Scheme Meeting.

YOUR PETITIONER THEREFORE HUMBL Y PRAYS THAT

- 1 The Scheme be sanctioned by this Honourable Court pursuant to section 86(2) of the Companies Act so as to be binding on the Company and the Scheme Creditors;
- 2 To this end, all necessary inquiries may be made, and directions may be made and given;

3 Such further or other relief may be granted as this Honourable Court sees fit.

Dated this 19th day of December 2023



Harney Westwood & Riegels
Attorneys-at-law for the Petitioner

THIS PETITION was presented by Harney Westwood & Riegels, Attorneys-at-Law for the Petitioner, whose address for service is 3rd Floor, Harbour Place, 103 South Church Street, PO Box 10240, Grand Cayman KY1-1002, Cayman Islands (Ref: 061110.0001-CAR).

NOTICE OF HEARING

TAKE NOTICE THAT the hearing of this Petition will take place at the Law Court, George Town, Grand

Cayman, Cayman Islands on 21st February 2024 at 10:00 am.

Any correspondence or communication with the Court relating to the hearing of this Petition should be addressed to the Registrar of the Financial Service Division of the Grand Court at PO Box 495, George Town, Grand Cayman KY-1106, Cayman Islands; Tel: 3459494296